Intensity Therapeutics Inc
NASDAQ:INTS
Operating Margin
Intensity Therapeutics Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
I
|
Intensity Therapeutics Inc
NASDAQ:INTS
|
13.9m USD | N/A | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
364.7B USD |
31%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
157.9B USD |
31%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
146.8B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
100.1B USD |
39%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
131.4B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
61.4B USD |
29%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
59.7B USD |
-7%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
Intensity Therapeutics Inc
Glance View
Intensity Therapeutics, Inc. engages in the operation a biotechnology company which develops novel immune-based therapeutic products for cancer treatment. The company is headquartered in Westport, Connecticut and currently employs 3 full-time employees. The company went IPO on 2023-06-30. The firm is engaged in developing an approach to treat solid tumor cancers. The company leverages its DfuseRx technology platform to create proprietary drug formulations. Its product candidates have the potential to induce an adaptive immune response that attacks the injected and non-injected tumors. The firm's lead product candidate, INT230-6, is in development for the treatment of patients with solid tumors, such as sarcoma and breast cancer patients. The Company, through Merck Sharpe & Dohme (Merck), evaluates INT230-6 with pembrolizumab. In addition, it also evaluates the combination INT230-6 with Bristol-Myers Squibb's anti-CTLA-4 antibody, ipilimumab. The company also has an agreement with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer (the INVINCIBLE study) (NCT04781725).
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Intensity Therapeutics Inc's most recent financial statements, the company has Operating Margin of 0%.
You don't have any saved screeners yet